15 8月 2022 by admin in UncategorizedComments Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates August 10, 2022
08 8月 2022 by admin in UncategorizedComments Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
04 8月 2022 by admin in UncategorizedComments NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results
04 8月 2022 by admin in UncategorizedComments Laronde Appoints John Mendlein as Chief Executive Officer
03 8月 2022 by admin in UncategorizedComments Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
01 8月 2022 by admin in UncategorizedComments Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease
28 7月 2022 by admin in UncategorizedComments KIRA PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR KP104, A BIFUNCTIONAL ANTIBODY FUSION PROTEIN, FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
06 7月 2022 by admin in UncategorizedComments Crescendo Biologics announces nomination of second proprietary clinical candidate from immuno-oncology Humabody VH development portfolio
06 7月 2022 by admin in UncategorizedComments NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec- 15-positive Tumors as reported in Laboratory Investigation
05 7月 2022 by admin in UncategorizedComments Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
22 6月 2022 by admin in UncategorizedComments Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annua
21 6月 2022 by admin in UncategorizedComments Arcellx Announces Closing Of Upsized Public Offering Of Common Stock And Underwriters’ Full Exercise Of Option To Purchase Additional Shares
21 6月 2022 by admin in UncategorizedComments Arcellx Announces Appointment Of Maryam Abdul-Kareem As General Counsel
15 6月 2022 by admin in UncategorizedComments Arcellx Announces Upsizing And Pricing Of Follow-On Public Offering
09 6月 2022 by admin in UncategorizedComments Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance
23 5月 2022 by admin in UncategorizedComments Arcellx Appoints Michelle Gilson As Chief Financial Officer
16 5月 2022 by admin in UncategorizedComments Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update
13 5月 2022 by admin in UncategorizedComments Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights
12 5月 2022 by admin in UncategorizedComments Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results
12 5月 2022 by admin in UncategorizedComments Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates
10 5月 2022 by admin in UncategorizedComments Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma
09 5月 2022 by admin in UncategorizedComments Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results
09 5月 2022 by admin in UncategorizedComments Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma
05 5月 2022 by admin in UncategorizedComments NextCure Provides Business Update and Reports First Quarter 2022 Financial Results
27 4月 2022 by admin in UncategorizedComments Tempest Announces Private Placement Financing of $15 Million
19 4月 2022 by admin in UncategorizedComments Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001
30 3月 2022 by admin in UncategorizedComments Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTA C TM Molecule for the Treatment of Friedreich Ataxia
29 3月 2022 by admin in UncategorizedComments Tempest Reports Year End 2021 Financial Results and Provides Business Update
24 3月 2022 by admin in UncategorizedComments Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
